Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

36.38 +0.83 (+2.32%)
Streaming Delayed Price Updated: 3:10 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate
Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the... 
Via Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
What 9 Analyst Ratings Have To Say About Protagonist Therapeutics
Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ: 
Via Benzinga
Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month
Following huge swings over the last two months, the biotech stock is now up 67% year to date. 
Via The Motley Fool
Exposures Product Safety
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A... 
Via Benzinga
Analyst Ratings For Protagonist Therapeutics
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A... 
Via Benzinga
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
MKM Partners raised the price target on Continental Resources, Inc. (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Evercore ISI Group raised Lear Corporation (NYSE: 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’... 
Via Benzinga
Exposures Product Safety
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
Where Protagonist Therapeutics Stands With Analysts
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ... 
Via Benzinga
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
28 Stocks Moving In Monday's Mid-Day Session
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical... 
Via Benzinga
Exposures Product Safety
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. 
Via InvestorPlace
Exposures Product Safety
Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug
Protagonist Therapeutics can now restart dosing patients in its rusfertide studies. 
Via Investor's Business Daily
Exposures Product Safety
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program
The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy
When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. 
Via InvestorPlace
58 Biggest Movers From Yesterday
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... 
Via Benzinga
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.